Tanshinone IIA reversed the doxorubicin resistance in SNU-719R and SNU-610R cells by decreasing the expression of MRP1, inducing cell cycle arrest in G2/M phase, downregulating the expression of Bcl-2, while upregulating the level of p53 and Bax to promote cancer cell apoptosis, upregulating the autophagy-related protein LC3B-II and downregulate p62 to facilitate cell autophagy (71). The gene discussed is BCL2; the disease is cancer.